Treatment Free Remission After Combination Therapy with Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Protocol No

HJKC3-0003

Staff Member

Ehab Atallah

Phase

Summary

The purpose of this study is to determine if adding asciminib to imatinib prior to a second attempt at stopping imatinib will lead to prolonged treatment free remission.

Objective

Treatment Free Remission After Asciminib plus Imatinib in CP-CML

Study Sites

Memorial Sloan Kettering Cancer Center - Monmouth Karmanos Cancer Institute University of Utah Huntsman Cancer Institute Lawrence And Idell Weisberg Cancer Treatment Center Moorland Reserve Health Center Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center - Bergen Froedtert Hospital

Status

OPEN TO ACCRUAL